Journal
BIOMEDICINES
Volume 9, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines9040372
Keywords
schizophrenia; endophenotypes; magnetic resonance spectroscopy; glutamatergic metabolites; anterior cingulate gyrus
Categories
Funding
- Jagiellonian University Medical College, Poland [N41/DBS/000292]
Ask authors/readers for more resources
Our study identified an objective molecular biomarker of schizophrenia outcome, based on biochemical indices in peripheral and cerebral tissues. Distinguishing two endophenotypes of schizophrenia, our research highlighted differences in life quality, symptoms, and neurotransmitter metabolites. The study suggests further investigation on the balance of microcircuits and redox systems for predicting potential biomarkers of neuropsychiatric diseases.
Despite extensive research, there is no convincing evidence of a reliable diagnostic biomarker for schizophrenia beyond clinical observation. Disorders of glutamatergic neurotransmission associated with N-methyl-D-aspartate (NMDA) receptor insufficiency, neuroinflammation, and redox dysregulation are the principal common mechanism linking changes in the periphery with the brain, ultimately contributing to the emergence of negative symptoms of schizophrenia that underlie differential diagnosis. The aim of the study was to evaluate the influence of these systems via peripheral and cerebral biochemical indices in relation to the patient's clinical condition. Using neuroimaging diagnostics, we were able to define endophenotypes of schizophrenia based on objective laboratory data that form the basis of a personalized approach to diagnosis and treatment. The two distinguished endophenotypes differed in terms of the quality of life, specific schizophrenia symptoms, and glutamatergic neurotransmission metabolites in the anterior cingulate gyrus. Our results, as well as further studies of the excitatory or inhibitory balance of microcircuits, relating the redox systems on the periphery with the distant regions of the brain might allow for predicting potential biomarkers of neuropsychiatric diseases, including schizophrenia. To the best of our knowledge, our study is the first to identify an objective molecular biomarker of schizophrenia outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available